MDNews - Eastern Pennsylvania/Northwest New Jersey

September/October 2011

Issue link: https://viewer.e-digitaledition.com/i/42856

Contents of this Issue

Navigation

Page 11 of 31

IMPROVING BREAST CANCER SURVIVAL RATES RECENT STUDIES HAVE revealed breast cancer patients at St. Luke's Hospital & Health Network have experienced survival rates higher than the national average. Such a success doesn't happen overnight, and for St. Luke's, it was the result of a multidisciplinary approach and the implementation of advanced techniques at several stages along the breast cancer continuum. "When you track survival for breast cancer patients, you start with your data from a minimum of fi ve to six years ago, and you have to be looking at data fi ve years before that to fi gure out how to implement things to begin a trend of consistent improvement," says Lee B. Riley, M.D., Ph.D., FACS, surgical oncologist and Medical Director of Oncology Services at St. Luke's. "My vision for improving breast cancer survival rates is a compounded interest vision. If every clinician improves survival by 1% by taking some sort of action within their purview — earlier diagnosis in radiology, better marking of margins in surgery, better radiation technology — you have a 5% to 10% improvement in survival. That alone may be more signifi cant than a new drug." In addition to commitment from all physicians involved in breast cancer care to improve survival rates, St. Luke's Hospital & Health Network's breast cancer program includes nurse navigators to help steer patients and their families through the breast cancer journey. Other elements that have contributed to improved survival rates include two tests — OncotypeDX® and MammaPrint® — used to measure tumors' genetic profi le, thus gauging their likelihood of recurrence. MammaPrint requires fresh tissue to be effective, and a system of coordina- tion allows samples from operating rooms across St. Luke's network to be sent to the Network Chief of Pathology's lab for preservation within 30 minutes. St. Luke's Hospital & Health Network is also one of only 10 hospitals in Pennsylvania to use MarginMarker®, a system of color-coding malignant breast tissue after excision based on how the tumor was positioned in the body. MarginMarker allows physicians to determine if all cancerous tissue has been removed. Dr. Burfeind cites multidisciplinary tumor boards as one of the major advances in lung cancer care in the last 15 years. In a League of Its Own "I'm a surveyor for the CoC, and I travel and mid-level practitioners. "We gather every week to discuss all new and returning lung cancer patients," says William R. Burfeind, Jr., M.D., FACS, Chief of Thoracic Surgery at St. Luke's Hospital & Health Network. "The advan- tage to such a gathering is that it provides a broad perspective for every patient. For example, some early-stage patients who may be primarily treated with surgery may also benefi t from chemotherapy later, and therefore having input from a medical oncologist is important. Some Stage IV patients who will be primarily treated by medical oncologists may benefi t from a thoracic surgeon's perspective. "There is an analogy that says, 'If you have a hammer, everything looks like a nail.' If you have one main way of treating something, you tend to treat it that way, but sometimes there are multiple 'best ways' to approach treatment. The Lung Tumor Board allows many specialists to develop a consensus; it's not uncommon for us to have 30 people, including 15 clinicians, in the room each week. Discussion can be straightforward, and it can also be lively. By having so many specialists present, a patient gets a balanced look at his or her care, and as a group, we can develop a treatment plan that is best for that patient." 12 | Eastern Pennsylvania/NW New Jersey MD NEWS MDNEWS.COM to other hospitals to evaluate their cancer programs," says Thomas Tachovsky, M.D., FACS, Oncology Quality Oversight at St. Luke's Hospital & Health Network. "I'm not allowed to survey my own hospital, of course, or any hospital in direct competi- tion with mine. I get a chance to see a variety of cancer programs of varying quality, and I feel like the program at St. Luke's Hospital & Health Network is the benchmark. When I come away from visiting a good program, I do so thinking, 'This program is as good as what we have at St. Luke's.' That being said, our journey is never over — we will continue to seek ways to improve." For more information about cancer care at St. Luke's Hospital & Health Network, visit www.slhn.org and select "Our Major Services." n

Articles in this issue

Links on this page

Archives of this issue

view archives of MDNews - Eastern Pennsylvania/Northwest New Jersey - September/October 2011